Skip to content
OpenCapital
Get started

Vivos Therapeutics, Inc. VVOS Q3 2025 earnings

Reported November 19, 2025 · Before market open

Revenue$6.8MMiss by $313.7K
EPS-$0.49Beat by $0.04
Revenue estimate$7.1M
EPS estimate-$0.53

Next report

Aug 18, 2026 (In 2 weeks)
Revenue estimate$5.6M
EPS estimate-$0.42

Versus estimates

Revenue

Q1 2026$5.1MBeat by $792.3KQ4 2025$3.8MMiss by $3.3M
Q3 2025$6.8MMiss by $313.7K
Q2 2025$3.8MBeat by $166.6KQ1 2025$3.0MMiss by $650.4KQ4 2024$3.7MMiss by $187.4K

Diluted EPS

Q1 2026-$0.52Miss by $0.07Q4 2025-$0.58Miss by $0.08
Q3 2025-$0.49Beat by $0.04
Q2 2025-$0.55Miss by $0.28Q1 2025-$0.45Miss by $0.01Q4 2024-$0.28Beat by $0.15

Ask the moment Vivos Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Vivos Therapeutics, Inc. report Q3 2025 earnings?
Vivos Therapeutics, Inc. (VVOS) reported Q3 2025 earnings on November 19, 2025 before market open.
What were Vivos Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Vivos Therapeutics, Inc. reported revenue of $6.8M and eps of $-0.49 for Q3 2025.
Did Vivos Therapeutics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $7.1M by $313.7K. EPS beat the consensus estimate of $-0.53 by $0.04.
How did Vivos Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 75.7% from $3.9M a year earlier and eps declined 22.5% from $-0.40.
Where can I find Vivos Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001493152-25-024289) and the 10-Q periodic report (0001493152-25-024253) directly on SEC EDGAR. The filing index links above go to sec.gov.